Dr. William Makis, MD
Dr. William Makis is a Canadian specialist in nuclear medicine and clinical oncology. He received his medical degree from McGill University and subsequently completed his residency in nuclear medicine and radiology there (2005–2010) (787 – Dr. William Makis–Shaun Newman Podcast, podcasts.apple.com, William Makis | Cross Cancer Institute, Edmonton | Research profile, researchgate.net).
After completing his residency, Dr. Makis, among others, at the McGill University Health Center (2005–2010) and then at the Brandon Regional Health Centre, Manitoba (2010–2014) (wikigenes.org). Since 2013, he has worked at the renowned Cross Cancer Institute in Edmonton, where he serves as a Nuclear Medicine Oncologist and Assistant Professor of Radiology at the University of Alberta (William Makis | Cross Cancer Institute, Edmonton | Research profile) (researchgate.net).
Dr. Makis has contributed to the diagnosis of over 10,000 cancer cases, particularly using imaging techniques such as PET/CT, and was involved in one of the largest therapy-based trial programs on 177Lu-DOTATATE (Lutathera) in North America with over 250 patients.
He has published more than 100 peer-reviewed scientific articles in international journals (in one podcast, Dr. Makis discusses he actually authored 800 studies).
In addition, Dr. Makis became active as a whistleblower after speaking out against bureaucracy in health authorities (Alberta Health Services, College of Physicians & Surgeons of Alberta) and is publicly active on Substack, in podcast format, and via social media (search.cpsa.ca).
Dr. William Makis, MD, is known for his critical stance on the COVID-19 vaccine:
- In October 2022, he wrote an open letter to the Canadian Medical Association (CMA) claiming that “80 young Canadian physicians” aged 25–55 had died suddenly since the introduction of the COVID-19 vaccine. This letter was reviewed by Reuters and the causality it claims between vaccination and deaths has been neither confirmed by autopsies nor statistically supported (reuters.com).
- Dr. Makis served as one of the co-authors of a systematic review of autopsy findings related to fatal myocarditis following COVID-19 vaccination, published in 2024. This publication concluded that approximately 74% of the cases examined had a possible vaccine role. However, the methodological assessment of this study has been significantly criticized in numerous media outlets and expert clarifications, and robust evidence of true causality is lacking.Fact-check platforms such as FactCheck.org, Reuters, and AFP emphasize that Dr. Makis’ claims often come from unconfirmed data, have been selectively interpreted, and do not meet scientific standards (factcheck.org, reuters.com).
Dr. Makis’ work as a private practice oncologist with off-label repurposed therapies
Dr. William Makis demonstrably began in September 2024, following the publication of aasten protocol in the Journal of Orthomolecular Medicine, to use ivermectin, fenbendazole and mebendazole as “off-label”, repurposed cancer drugs (isom.ca).
- The protocol, published on 19. September 2024, is entitled “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol” and was developed jointly by Makis and numerous colleagues (isom.ca).
- Also in October 2024, Dr. Makis was active on social media, for example on X (formerly Twitter), where he claimed:
“First-in-the-World Ivermectin, Mebendazole, and Fenbendazole Protocol in Cancer has been peer-reviewed and published on September 19, 2024!” (x.com, science.feedback.org).
In interviews and podcasts, he explained that he now has over 1,000 cancer patients receiving this combination – often in the form of ivermectin + fenbendazole or ivermectin + mebendazole (facebook.com).
Assessment of the Evidence
- The underlying protocol publication is largely based on preclinical studies (in vitro and animal experiments) and individual case reports – not on randomized clinical trials (science.feedback.org).
- Medical science reviewers such as Science Feedback rate the underlying evidence as insufficient to claim efficacy in human cancer (science.feedback.org).
Conclusion: Dr. Makis has been using ivermectin, mebendazole, and fenbendazole as off-label cancer drugs since September 2024, based on a hybrid orthomolecular protocol. However, this use is currently based only on preliminary, non-clinically validated evidence, without robust trial data.
This off-label use of “Kickl’s Horseworm Remedy” as a repurposed cancer drug is by no means illegible and I reject it, as it goes against all therapeutic recommendations of the Medical Association and professional societies!
The approximately 27,000 entries published in the Google.Scholar research database suggest scientific evidence, which, however, has been strictly rejected by experts such as Dr. Mückstein, the BSGA in Austria, the EU in the form of the EMA, and even the WHO.
Since Dr. Since Dr. Makis floods social media with his unscientific “case studies” – which consist primarily of emails – and is therefore regularly investigated by the Canadian authorities, I’m presenting some of his articles here as a basis for discussion and to warn against it!
some Cases that Dr. William Makis published on Substack
by no means this are real cases. Dr. Makis shows emails that he has got by patients. This might be completely fraudulant!
34-year-old patient with stage 3 breast cancer, 80% tumor regression with ivermectin and mebendazole | 18.6.25
Comment: Every oncologist laughs at this, as established methods achieve good results in stage 3. Therefore, there is no reason tohe is using any off-label repurposed regimen.
Stage III means:
-
-
large primary tumor (>5 cm)
-
Involvement of regional lymph nodes (axillary or infraclavicular)
-
No evidence of distant metastases (M0)
-
According to international data (SEER, American Cancer Society, ESMO, NCCN):
-
-
Overall 5-year survival rate (all subtypes):
approx. 60–72% -
5-year disease-free remission rate (after complete therapy):
approx. 45–60%, depending on tumor biology
-
- 80-year-old woman with squamous cell carcinoma tumor-free with fenbendazole. Biopsy confirms diagnosis, oral and local fenbendazole eradicates the cancer | Sept. 28, 2024
- 26-year-old man with 9 cm B-cell lymphoma is tumor-free after 5 months of ivermectin + fenbendazole | June 15, 2025
- Brain tumor-free with nanoencapsulated ivermectin – peer reviewed case report | June 15, 2025
- 66-year-old man with large pancreatic carcinoma (pancreas) and a solitary liver metastasis, 99.7% tumor-free after several months of ivermectin and fenbendazole | June 15, 2025
Comment
As soon as I have time, I’ll add more cases from Dr. Makis. I think he’s published about 100 such “pseudo-therapies” so far. I’m only presenting these cases to warn against them and to raise this issue for the authorities to discuss – this really needs to be put a stop to via the Digital Service Act in the form of appropriate EU censorship, as more and more patients are coming forward and saying they want such therapies!
Google CENSORSHIP!
Google censors my homepage quite a bit, sometimes I am not even able to find my articles on Google. So please sign up for the newsletter and share it with friends or via Facebook and use the search function on my website. Follow me on Twitter, where I also announce important articles.